Male hormonal contraception

American Journal of Obstetrics and Gynecology

Volumn 190, Issue 4 SUPPL., 2004, Pages

  Wang, Christina ^a,b   Swerdloff, Ronald S ^a  

^a HARBOR UCLA MEDICAL CENTER   (United States)

^b General Clinical Research Center   (United States)

Author keywords

Androgens; Gonadotropin releasing hormone antagonists; Progestins; Suppression of spermatogenesis

Indexed keywords

ANDROGEN; ANDROSTANOLONE; CONTRACEPTIVE AGENT; CYPROTERONE ACETATE; DESOGESTREL; ESTROGEN; GESTAGEN; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; NANDROLONE; NORETHISTERONE ACETATE; NORETHISTERONE ENANTATE; SEX HORMONE; TESTOSTERONE; TESTOSTERONE 4 BUTYLCYCLOHEXANECARBOXYLATE; TESTOSTERONE ENANTATE; TESTOSTERONE UNDECANOATE; TRESTOLONE;

ACNE; AZOOSPERMIA; BLOOD TOXICITY; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; ERYTHROCYTOSIS; ETHNIC DIFFERENCE; GEOGRAPHY; HORMONAL CONTRACEPTION; HUMAN; INJECTION SITE; MALE; NONHUMAN; OLIGOSPERMIA; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; SKIN DISEASE; SPERMATOGENESIS; SYSTEMATIC REVIEW; TESTOSTERONE BLOOD LEVEL; WEIGHT GAIN;

EID: 2342435686     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajog.2004.01.057     Document Type: Article

References (81)

1. Trussell J, Kost K. Contraceptive failure in the United States: a critical review of literature. Stud Fam Plann 1987;18:237-83.
2. Liu X, Li S. Vasal sterilization in China. Contraception 1993;48:255-65.
3. Tapanainen JS, Vaskivuo T, Aitoomaki K, Huhtaniemi IT. Inactivating FSH receptor mutations and gonadal dysfunction. Mol Cell Endocrinol 1998;145:239-45.
4. Themmen APN, Huhtaniemi IT. Mutations of gonadotropins and gonadotropin receptors: elucidating the physiology and pathophysiology of pituitary-gonadal function. Endocr Rev 2000;21:551-83.
5. Layman LC. Mutations in the follicle-stimulating hormone-beta (FSH beta) and FSH receptor genes in mice and humans. Semin Reprod Med 2000;18:5-10.
6. Wang C, Yeung KC. Use of low-dosage cyprosterone acetate as a male contraceptive. Contraception 1980;21:245-72.
7. Roy S. Experience in the development of hormonal contraceptive for the male. In: Asch RH, editor. Recent advances in human reproduction. Rome: Fondazione per gli Studi Sulla Riproduzione Umana; 1985. p. 95-104.
8. Amory JK, Bremner W. Endocrine regulation of testicular function in men: implications for contraceptive development. Mol Cell Endocrinol 2001;182:175-9.
9. Zhengwei Y, Wreford NG, Schlatt S, Weinbauer GF, Nieschlag E, McLachlan RI. Acute and specific impairment of spermatogonial development by GnRH antagonist-induced gonadotrophin withdrawal in the adult macaque (Macaca fascicularis). J Reprod Fertil 1998;112:139-47.
10. Zhengwei Y, Wreford NG, Royce P, de Kretser DM, McLachlan RI. Stereological evaluation of human spermatogenesis after suppression by testosterone treatment: heterogeneous pattern of spermatogenic impairment. J Clin Endocrinol Metab 1998;83:1284-91.
11. O'Donnell L, Narula A, Balourdes G, Gu YQ, Wreford NG, Robertson DM, et al. Impairment of spermatogonial development and spermiation after testosterone-induced gonadotropin suppression in adult monkeys (Macaca fascicularis). J Clin Endocrinol Metab 2001;86:1814-22.
12. Sinha-Hikim AP, Swerdloff RS. Temporal and stage-specific changes in spermatogenesis of rat after gonadotropin deprivation by a potent gonadotropin-releasing hormone antagonist treatment. Endocrinology 1993;133:2161-70.
13. Sinha Hikim AP, Rajavashisth TB, Sinha Hikim I, Lue Y, Bonavera JJ, Leung A, et al. Significance of apoptosis in the temporal and stage-specific loss of germ cells in the adult rat after gonadotropin deprivation. Biol Reprod 1997;57:1193-201.
14. Lue Y, Hikim AP, Wang C, Im M, Leung A, Swerdloff RS. Testicular heat exposure enchances the suppression of spermatogenesis by testosterone in rats: the "two-hit" approach to male contraceptive development. Endocrinology 2000;141:1414-24.
15. Saito K, O'Donnell L, McLachlan RI, Robertson DM. Spermiation failure is a major contributor to early spermatogenic suppression caused by hormone withdrawal in adult rats. Endocrinology 2000;141:2779-85.
16. World Health Organization Task Force on Methods for the Regulation of Male Fertility. Contraceptive efficacy of testosterone-induced azoospermia in normal men. Lancet 1990;336:955-9.
17. World Health Organization Task Force on Methods for the Regulation of Male Fertility. Contraceptive efficacy of testosterone-induced azoospermia and oligozoospermia in normal men. Fertil Steril 1996;65:821-9.
18. Matsumoto AM. Effects of chronic testosterone administration in normal men: safety and efficacy of high dose testosterone and parallel dose-dependent suppression of luteinizing, follicle-stimulating hormone, and sperm production. J Clin Endocrinol Metab 1990;70:282-7.
19. Meriggiola MC, Bremner WJ, Paulsen CA, Valdiserri A, Incorvaia L, Motta R, et al. A combined regimen of cyproterone acetate and testosterone enanthate as a potentially highly effective male contraceptive. J Clin Endocrinol Metab 1996;81:3018-23.
20. Arsyad KM. Sperm function in Indonesian men treated with testosterone enanthate. Int J Androl 1993;16:355-61.
21. Handelsman DJ, Conway AJ, Boylan LM. Suppression of human spermatogenesis by testosterone implants in man. J Clin Endocrinol Metab 1992;75:1326-32.
22. Handelsman DJ, Conway AJ, Howe CJ, Turner L, Mckey MA. Establishing the minimum effective dose and additive effects of depot progestin in suppression of human spermatogenesis by a testosterone depot. J Clin Endocrinol Metab 1996;81:4113-21.
23. Behre HM, Baus S, Kliesch S, Keck C, Simoni M, Nieschlag N. Potential of testosterone buciclate for male contraception: endocrine differences between responders and non-responders. J Clin Endocrinol Metab 1995;80:2394-403.
24. Zhang G-Y, Gu Y-Q, Wang X-H, Cui Y-G, Bremner WJ. A clinical trial of injectable testosterone undecanoate as a potential male contraceptive in normal Chinese men. J Clin Endocrinol Metab 1999;84:3642-7.
25. Zhang GY, Gu YO, Wang XH, Cui YG, Bremner WJ. Pharmacokinetic study of injectable testosterone undecanoate in hypogonadal men. J Androl 1998;19:761-8.
26. Behre HM, Abshagen K, Oettel M, Hubler D, Nieschlag E. Intramuscular injection of testosterone undecanoate for the treatment of male hypogonadism: phase I studies. Eur J Endocrinol 1999;140:414-9.
27. Nieschlag E, Buchter D, von Eckardstein S, Abshagen K, Simoni S, Behre HM. Repeated intramuscular injections of testosterone undecanoate for substitution therapy of hypogonadal men. Clin Endocrinol 1999;51:757-63.
28. Kamischke A, Ploger D, Venherm S, von Eckardstein S, von Eckardstein A, Nieschlag E. Intramuscular testosterone undecanoate with or without oral levonorgestrel: a randomized placebo-controlled feasibility study for male contraception. Clin Endocrinol 2000;53:43-52.
29. Gu YQ, Wang XH, Xu D, Peng L, Cheng LF, Huang MK, et al. A multicenter contraceptive efficacy study of injectable testosterone undecanoate in healthy Chinese men. J Clin Endocrinol Metab 2003;88:562-8.
30. Wu FCW, Farley TMM, Peregoudov A, Waites GMH, World Health Organization Task Force on Methods for the Regulation of Male Fertility. Effects of testosterone enanthate in normal men: experience from a multicenter contraceptive efficacy study. Fertil Steril 1996;65:626-36.
31. Bhasin S, Woodhouse L, Casaburi R, Singh AB, Bhasin D, Berman N, et al. Testosterone dose-response relationships in healthy young men. Am J Physiol Endocrinol Metab 2001;281:E1172-81.
32. Freidl KE, Jones RE, Hannan CJ, Plymate SJ. The administration of pharmacological doses of testosterone or 19-nortestosterone to normal men is not associated with increased insulin secretion or impaired glucose tolerance. J Clin Endocrinol Metab 1989;68:971.
33. Bagatell CJ, Herman JR, Matsumoto AM, Rivier JE, Bermner WJ. Metabolic and behavioral effects of high-dose, exogenous testosterone in healthy men. J Clin Endocrinol Metab 1994;79:561-7.
34. Barrett-Connor E. Lower endogenous androgen levels and dyslipidemia in men with non-insulin dependent diabetes mellitus. Ann Int Med 1992;117:807-11.
35. Simon D, Charles M-A, Nahoul K, Orssand G, Kremski J, Hully V, et al. Association between plasma total testosterone and cardiovascular risk factors in healthy adult men: The Telecom Study. J Clin Endocrinol Metab 1997;82:682-5.
36. McConnell JD. Epidemiology, etiology, pathophysiology, and diagnosis of benign prostatic hyperplasia. In: Walsh K, Retik AB, Vaughan ED, Wein AJ, editors. Campbell's urology. 7th ed. Philadelphia: WB Saunders; 1991. p. 1429-52.
37. McConnell JD. Physiologic basis of endocrine therapy for prostatic cancer. Urol Clin North Am 1991;19:1-13.
38. Pienta KJ. Etiology, epidemiology and prevention of carcinoma of the prostate. In: Walsh PC, Retik AB, Vaughan ED Wein AJ, editors. Campbell's urology. 7th ed. Philadelphia: WB Saunders; 1997. p. 2489-96.
39. Kumar N, Didolkar AK, Monder C, Bardin CW, Sundaran K. The biological activity of 7 α-methyl-19-nortestosterone is not amplified in male reproductive tract as is that of testosterone. Endocrinology 1992;130:3677-83.
40. Cummings DE, Kumar N, Bandin CW, Sundaram K, Bremner WJ. Prostate-sparing effects in primates of the potent androgen 7α-methyl-19nortestosterone: a potential alternative to testosterone for androgen replacement and male contraception. J Clin Endocrinol Metab 1998;83:4212-9.
41. Anderson RA, Martin CW, Kung AWC, Everington D, Pun TC, Tan KCB, et al. 7α-Methyl-19-nortestosterone maintains sexual behavior and mood in hypogonadal men. J Clin Endocrinol Metab 1999;84:3556-62.
42. von Eckardstein S, Noe G, Brache V, Nieschlag E, Croxatto H, Alvarez F, et al. A clinical trial of 7 (alpha)-methyl-19-nostestosterone implants for possible use as a long-acting contraceptive for men. J Clin Endocrinol Metab 2003;88:5232-9.
43. Schearer SB, Alvarez-Sanchez F, Anselmo J, Brenner P, Continlo E, Latham-Foundes A, et al. Hormonal contraception for men. Int J Androl 1978;2(Suppl):680-712.
44. Paulsen CA, Bremner WJ, Leonard JM. Male contraception: clinical trials. In: Mishell DR Jr (editor). New York: Raven Press; 1982. p. 157-70.
45. Knuth UA, Nieschlag E. Endocrine approaches to male fertility control. Clin Endocrinol Metab 1987;1:113-31.
46. Knuth UA, Yeung CH, Nieschlag E. Combination of 19-nortestosterone- hexylphenylpropionate (Anadur) and depot-medroxyprogesterone-acetate (Clinovir) for male contraception. Fertil Steril 1989;51:1011-8.
47. Wu FC, Aitken RJ. Suppression of sperm function by depot medroxyprogesterone acetate and testosterone enanthate in steroid male contraception. Fertil Steril 1989;51:691-8.
48. World Health Organization Task Force on Methods for the Regulation of Male Fertility. Comparison of two androgens plus depo-medroxyprogesterone acetate for suppression to azoospermia in Indonesian men. Fertil Steril 1993;60:1062-8.
49. Turner L, Conwaty AJ, Jimenez M, Liu PY, Forbes E, McLachlan RI, et al. Contraceptive efficacy of a depot progestin and androgen combination in men. J Clin Endocrinol Metab 2003;88:4659-67.
50. Bebb RA, Anawalt BD, Christiansen RB, Paulsen CA, Bremner WJ, Matsumoto AM. Combined administration of levonorgestrel and testosterone induces more rapid and effective suppression of spermatogenesis than testosterone alone: a promising male contraceptive approach. J Clin Endocrinol Metab 1996;81:757-62.
51. Anawalt BD, Bebb RA, Bremner WJ, Matsumoto AM. A lower dosage levonorgestrel and testosterone combination effectively suppresses spermatogenesis and circulating gonadotropin levels with fewer metabolic effects than higher dosage combinations. J Androl 1999;20:407-14.
52. Buchter D, von Eckardstein S, von Eckardstein A, Kamischke A, Simoni M, Behre HM, et al. Clinical trial of transdermal testosterone and oral levonorgestrel for male contraception. J Clin Endocrinol Metab 1999;84:1244-9.
53. Gonzalo ITG, Swerdloff RS, Nelson AL, Celvenger B, Garcia R, Berman N, et al. Levonorgestrel implants (Norplant II) for male contraception clinical trials: combination with transdermal and injectable testosterone. J Clin Endocrinol Metab 2002;87:3562-72.
54. Gao ES, Lin CH, Gui YL, Li LM, He CH. Inhibiting effects of Sino-implants plus testosterone undecanoate (TU) on spermatogenesis in Chinese men. Reprod Contraception 1999;10:98-105.
55. Pollanen P, Nikkanen V, Huhtaniemi I. Combination of subcutaneous levonorgestrel implants and transdermal dihydrotestosterone gel for male hormonal contraception. Int J Androl 2001;24:369-80.
56. Wu FCW, Balasubramanian R, Mulders TMT, Coelingh-Bennink HJT. Oral progestogen combined with testosterone as a potential male contraceptive: additive effects between desogestrel and testosterone enanthate in suppression of spermatogenesis, pituitary-testicular axis, and lipid metabolism. J Clin Endocrinol Metab 1999;84:112-22.
57. Anawalt BD, Herbst KL, Matsumoto AM, Mulders TMT, Coelingh-Bennink HJT, Bremner WJ. Desogestrel plus testosterone effectively suppresses spermatogenesis but also causes modest weight gain and high-density lipoprotein suppression. Fertil Steril 2000;74:707-14.
58. Martin CW, Riley SC, Everington D, Groome NP, Riermersma RA, Baird DT, et al. Dose-finding study of oral desogestrel with testosterone pellets for suppression of the pituitary-testicular axis in normal men. Hum Reprod 2000;15:1515-24.
59. Kinnibergh D, Anderson RA, Baird DT. Suppression of spermatogenesis with desogestrel and testosterone pellets is not enhanced by addition of Finasteride. J Androl 2001;22:88-95.
60. Anderson RA, Kinniburgh D, Baird DT. Suppression of spermatogenesis by etonogestrel implants with depot testosterone: potential for long-acting male contraception. J Clin Endocrinol Metab 2002;87:3640-9.
61. Kamischke A, Diebacker J, Nieschlag E. Potential of norethisterone enanthate for male contraception: pharmacokinetics and suppression of pituitary and gonadal function. Clin Endocrinol 2000;53:351-8.
62. Kamischke A, Heuermann T, Kruger K, von Eckardstein S, Schellschmidt I, Rubig A, et al. An effective hormonal male contraceptive using testosterone undecanoate with oral or injectable norethisterone preparations. J Clin Endocrinol Metab 2002;87:530-9.
63. Meriggiola MC, Bremner WJ, Costantino A, Pavani A, Capelli H, Flamigni C. An oral regimen of cyproterone acetate and testosterone undecanoate for spermatogenic suppression in men. Fertil Steril 1997;68:844-50.
64. Wang C, Berman NG, Veldhuis JD, Der T, McDonald V, Steiner B, et al. Graded testosterone infusions distinguish gonadotropin negative feedback responsiveness in Asian and white men - a Clinical Research Center Study. J Clin Endocrinol Metab 1998;83:870-6.
65. Anderson RA, Wallace AM, Wu FC. Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study: III, higher 5 alpha-reductase activity in oligozoospermic men administered supraphysiological doses of testosterone. J Clin Endocrinol Metab 1996;81:902-8.
66. McLachlan RI, McDonald J, Rushford D, Robertson DM, Garrett C, Baker HW. Efficacy and acceptability of testosterone implants, alone or in combination with a 5 alpha-reductase inhibitor, for male hormonal contraception. Contraception 2000;62:73-8.
67. Santner SJ, Albertson B, Zhang GY, Zhang GH, Santulli M, Wang C, et al. Comparative rates of androgen production and metabolism in Caucasian and Chinese subjects. J Clin Endocrinol Metab 1998;83:2104-9.
68. Johnson L, Barnard JJ, Rodriguez L, Smith EC, Swerdloff RS, Wang XH, et al. Ethnic difference in testicular structure and spermatogenic potential may predispose testes of Asian men to a heightened sensitivity to steroidal contraceptives. J Androl 1998;19:348-57.
69. Sinha-Hikim A, Wang C, Lue YH, Johnson L, Wang XH, Swerdloff RS. Spontaneous germ cell apoptosis in human: evidence for ethnic differences in the susceptability of germ cells to programmed cell death. J Clin Endocrinol Metab 1998;83:152-6.
70. Cummings DE, Bremner WJ. Prospects for new hormonal male contraceptives. Endocrinol Metabol Clin North Am 1994;22:893-922.
71. Bhasin S, Heber D, Steiner BS, Handelsman DJ, Swerdloff RS. Hormonal effects of gonadotropin-releasing hormone (GnRH) agonist and androgen. J Clin Endocrinol Metab 1985;60:998-1003.
72. Bhasin S, Steiner B, Swerdloff R. Does constant infusion of gonadotropin-releasing hormone agonist lead to greater suppression of gonadal function in man than its intermittent administration? Fertil Steril 1985;44:96-101.
73. Pavlou SN, Interlandi JW, Wakefield G, Rivier J, Vale W, Rabin D. Heterogeneity of sperm density profiles following 16-week therapy with continuous infusion of high-dose LHRH analog plus testosterone. J Androl 1986;7:228-33.
74. Bhasin S, Heber D, Steiner B, Peterson M, Blaisch B, Campfield LA, et al. Hormonal effects of GnRH agonist in the human male: II, testosterone enhances gonadotrophin suppression induced by GnRH agonist. Clin Endocrinol 1984;20:119-28.
75. Pavlou SN, Wakefield GB, Island DP, Hoffman PG, LePage ME, Chan RL, et al. Suppression of pituitary-gonadal function by a potent new luteinizing hormone-releasing hormone antagonist in normal men. J Clin Endocrinol Metab 1987;64:931-6.
76. Tom L, Bhasin S, Salameh W, Steiner B, Peterson M, Sokol RZ, et al. Induction of azoospermia in normal men with combined Nal-Glu gonadotropin-releasing hormone antagonist and testosterone enanthate. J Clin Endocrinol Metab 1992;75:476-83.
77. Bagatell CJ, Matsumoto AM, Christensen RB, Rivier JE, Bremner WJ. Comparison of a gonadotropin releasing-hormone antagonist plus testosterone (T) versus T alone as potential male contraceptive regimens. J Clin Endocrinol Metab 1993;77:427-32.
78. Behre HM, Klein B, Steinmeyer E, McGregor GP, Voigt K, Nieschlag E. Effective suppression of luteinizing hormone and testosterone by single doses of the new gonadotropin-releasing hormone antagonist cetrorelix (SB-75) in normal men. J Clin Endocrinol Metab 1992;75:393-8.
79. Behre HM, Kliesch S, Puhse G, Reissmann T, Nieschlag E. High loading and low maintenance doses of a gonadotropin-releasing antagonist effectively suppress serum luteinizing hormone, follicle-stimulating hormone, and testosterone in normal men. J Clin Endocrinol Metab 1997;82:1403-8.
80. Swerdloff RS, Bagatell CJ, Wang C, Anawalt BD, Steiner B, Berman N, et al. Suppression of spermatogenesis in man induced by Nal-Glu gonadotropin releasing hormone antagonist and testosterone enanthate is maintained by testosterone enanthate alone. J Clin Endocrinol Metab 1998;83:3527-33.
81. Behre HM, Kliesch S, Lemcke B, von Eckardstein S, Nieschlag E. Suppression of spermatogenesis to azoospermia by combined administration of GnRH antagonist and 19-nortestosterone cannot be maintained by this non-aromatizable androgen alone. Hum Reprod 2001;16:2570-7.